Kalydeco 150 MG tablet 56S
Ended Awarded Last action
- Contract number
- SPE2DR26FHKV5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,658
Award facts
- Contract value 100% obligated
- $38,657.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $38,657.64 to DMS Pharmaceutical Group Inc. for Kalydeco 150 mg tablets (56-count units) on January 13, 2026, with an ultimate completion date of January 14, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected through firm fixed-price pricing without a set-aside designation. The delivery order will be performed in Park Ridge, Illinois and is funded through the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, valued at $499.999 billion with a ceiling date of December 31, 2036, authorizes DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors under this contract vehicle, with demonstrated capability across diverse pharmaceutical categories including specialty drugs, biologics, vaccines, and routine medications for military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FHKV5?
SPE2DR26FHKV5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FHKV5 worth?
The government has obligated $38,658 on SPE2DR26FHKV5.
Is contract SPE2DR26FHKV5 an order under another contract?
Yes. SPE2DR26FHKV5 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKV5 competed?
The extent of competition for SPE2DR26FHKV5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award